Outcomes	O

The	O
study	O
objective	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
BRH	O
at	O
a	O
dose	O
of	O
32	O
mg	O
three	O
times	O
per	O
day	O
in	O
patients	O
with	O
moderate	O
COVID	O
‐	O
19	O
.	O

The	O
primary	O
and	O
secondary	O
outcomes	O
were	O
assessed	O
during	O
the	O
study	O
period	O
of	O
14	B-TimeFrame
days	I-TimeFrame
.	O

The	O
primary	O
end	O
points	O
were	O
the	O
time	B-PrimaryOutcome
to	I-PrimaryOutcome
clinical	I-PrimaryOutcome
recovery	I-PrimaryOutcome
and	O
the	O
deterioration	B-PrimaryOutcome
rate	I-PrimaryOutcome
after	I-PrimaryOutcome
initiation	I-PrimaryOutcome
of	I-PrimaryOutcome
medications	I-PrimaryOutcome
.	O

Clinical	O
recovery	O
was	O
defined	O
as	O
clinical	B-OutcomeDefinition
symptoms	I-OutcomeDefinition
(	I-OutcomeDefinition
fever	I-OutcomeDefinition
and	I-OutcomeDefinition
respiratory	I-OutcomeDefinition
symptoms	I-OutcomeDefinition
)	I-OutcomeDefinition
returning	I-OutcomeDefinition
to	I-OutcomeDefinition
normal	I-OutcomeDefinition
over	I-OutcomeDefinition
48	I-OutcomeDefinition
hours	I-OutcomeDefinition
.	O

Disease	O
deterioration	O
was	O
defined	O
as	O
the	O
presence	B-OutcomeDefinition
of	I-OutcomeDefinition
respiratory	I-OutcomeDefinition
distress	I-OutcomeDefinition
,	I-OutcomeDefinition
respiratory	I-OutcomeDefinition
rate	I-OutcomeDefinition
≥	I-OutcomeDefinition
30	I-OutcomeDefinition
times	I-OutcomeDefinition
/	I-OutcomeDefinition
minute	I-OutcomeDefinition
,	I-OutcomeDefinition
oxygen	I-OutcomeDefinition
saturation	I-OutcomeDefinition
≤	I-OutcomeDefinition
93	I-OutcomeDefinition
%	I-OutcomeDefinition
in	I-OutcomeDefinition
the	I-OutcomeDefinition
resting	I-OutcomeDefinition
state	I-OutcomeDefinition
,	I-OutcomeDefinition
and	I-OutcomeDefinition
oxygenation	I-OutcomeDefinition
index	I-OutcomeDefinition
≤	I-OutcomeDefinition
300	I-OutcomeDefinition
mmHg	I-OutcomeDefinition
.	I-OutcomeDefinition

The	O
secondary	O
outcomes	O
assessed	O
the	O
virologic	B-SecondaryOutcome
clearance	I-SecondaryOutcome
during	B-TimeFrame
the	I-TimeFrame
study	I-TimeFrame
period	I-TimeFrame
(	O
SARS	B-OutcomeDefinition
‐	I-OutcomeDefinition
CoV	I-OutcomeDefinition
‐	I-OutcomeDefinition
2	I-OutcomeDefinition
‐	I-OutcomeDefinition
negative	I-OutcomeDefinition
conversion	I-OutcomeDefinition
within	I-OutcomeDefinition
20	I-OutcomeDefinition
days	I-OutcomeDefinition
,	I-OutcomeDefinition
rate	I-OutcomeDefinition
of	I-OutcomeDefinition
SARS	I-OutcomeDefinition
‐	I-OutcomeDefinition
CoV	I-OutcomeDefinition
‐	I-OutcomeDefinition
2	I-OutcomeDefinition
‐	I-OutcomeDefinition
negative	I-OutcomeDefinition
conversion	I-OutcomeDefinition
)	O
,	O
clinical	B-SecondaryOutcome
follow	I-SecondaryOutcome
‐	I-SecondaryOutcome
up	I-SecondaryOutcome
(	O
clinical	B-OutcomeDefinition
remission	I-OutcomeDefinition
rate	I-OutcomeDefinition
,	I-OutcomeDefinition
time	I-OutcomeDefinition
to	I-OutcomeDefinition
fever	I-OutcomeDefinition
remission	I-OutcomeDefinition
,	I-OutcomeDefinition
rate	I-OutcomeDefinition
of	I-OutcomeDefinition
significant	I-OutcomeDefinition
improvement	I-OutcomeDefinition
in	I-OutcomeDefinition
chest	I-OutcomeDefinition
CT	I-OutcomeDefinition
,	I-OutcomeDefinition
percentage	I-OutcomeDefinition
of	I-OutcomeDefinition
patients	I-OutcomeDefinition
requiring	I-OutcomeDefinition
oxygen	I-OutcomeDefinition
therapy	I-OutcomeDefinition
,	I-OutcomeDefinition
and	I-OutcomeDefinition
discharge	I-OutcomeDefinition
rate	I-OutcomeDefinition
within	B-TimeFrame
20	I-TimeFrame
days	I-TimeFrame
)	O
,	O
and	O
the	O
occurrence	B-SecondaryOutcome
of	I-SecondaryOutcome
side	I-SecondaryOutcome
effects	I-SecondaryOutcome
.	O

Deteriorated	O
patients	O
who	O
progressed	O
to	O
severe	O
or	O
critical	O
condition	O
were	O
withdrawn	O
from	O
the	O
study	O
.	O

Chest	O
CT	O
was	O
blindly	O
interpreted	O
at	O
the	O
baseline	O
(	O
7	O
days	O
before	O
randomization	O
)	O
and	O
after	O
randomization	O
(	O
7	O
days	O
±	O
1	O
day	O
)	O
by	O
two	O
experienced	O
radiologists	O
.	O

A	O
semiquantitative	O
scoring	O
system	O
was	O
used	O
to	O
quantitatively	O
assess	O
the	O
pulmonary	O
improvement	O
,	O
and	O
the	O
cases	O
were	O
divided	O
into	O
the	O
following	O
five	O
categories	O
:	O
no	O
improvement	O
(	O
<	O
10	O
%	O
absorption	O
)	O
,	O
mild	O
improvement	O
(	O
10	O
–	O
30	O
%	O
absorption	O
)	O
,	O
improvement	O
(	O
30	O
–	O
60	O
%	O
absorption	O
)	O
,	O
remarkable	O
improvement	O
(	O
60	O
–	O
90	O
%	O
absorption	O
)	O
,	O
and	O
complete	O
improvement	O
(	O
>	O
90	O
%	O
absorption	O
)	O
.	O

All	O
AEs	O
reported	O
during	O
the	O
study	O
were	O
recorded	O
and	O
graded	B-OutcomeDefinition
according	I-OutcomeDefinition
to	I-OutcomeDefinition
the	I-OutcomeDefinition
Common	I-OutcomeDefinition
Terminology	I-OutcomeDefinition
Criteria	I-OutcomeDefinition
for	I-OutcomeDefinition
Adverse	I-OutcomeDefinition
Events	I-OutcomeDefinition
,	I-OutcomeDefinition
version	I-OutcomeDefinition
5	I-OutcomeDefinition
.	I-OutcomeDefinition
0	I-OutcomeDefinition
.	O

Assessments	O
of	O
laboratory	O
parameters	O
,	O
physical	O
condition	O
,	O
chest	O
images	O
,	O
and	O
nucleic	O
acid	O
test	O
results	O
were	O
performed	O
at	O
baseline	O
,	O
during	O
the	O
study	O
period	O
,	O
and	O
at	O
the	O
3	O
‐	O
week	O
follow	O
‐	O
up	O
.	O

Assessments	O
were	O
also	O
conducted	O
at	O
the	O
end	O
of	O
the	O
study	O
period	O
or	O
the	O
time	O
of	O
withdrawal	O
,	O
as	O
appropriate	O
.	O

